Tarsus Pharmaceuticals (TARS) Cash & Current Investments (2019 - 2026)

Tarsus Pharmaceuticals' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $102.2 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 74.95% year-over-year to $102.2 million; the TTM figure through Mar 2026 stood at $102.2 million (down 74.95% YoY), while the FY2025 annual figure was $417.3 million, up 340.07% from the prior year.
• Cash & Current Investments was $102.2 million for Q1 2026 at Tarsus Pharmaceuticals, down from $417.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $417.3 million in Q4 2025 to a low of $94.8 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $262.5 million across 5 years, with a median of $245.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments jumped 340.07% in 2025, then plunged 74.95% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $217.0 million in 2022, then gained by 4.8% to $227.4 million in 2023, then plunged by 58.31% to $94.8 million in 2024, then jumped by 340.07% to $417.3 million in 2025, then tumbled by 75.51% to $102.2 million in 2026.
• The last three Cash & Current Investments figures came in at $102.2 million (Q1 2026), $417.3 million (Q4 2025), and $401.8 million (Q3 2025), per Business Quant data.